A Look At ICON (ICLR) Valuation After New Advarra Clinical Trial Network Partnership

ICON (NasdaqGS:ICLR) has drawn fresh attention after announcing a definitive partnership with Advarra to build a connected, research ready clinical trial site network that aims to simplify operations and widen trial access.

See our latest analysis for ICON.

Despite the Advarra agreement and recent conference appearances, ICON’s recent share price return has been mixed, with modest gains over the past month but a much weaker 90 day share price return of 44.9% and a 1 year total shareholder return decline of 43.4%.

If this clinical trials update has you thinking about where else technology and healthcare intersect, it could be a good time to size up 36 healthcare AI stocks

With ICON’s shares down sharply over 1 year, yet trading at a reported 53% discount to estimated intrinsic value and 37% below analyst targets, the key question is whether there is a buying opportunity here or if markets are already pricing in future growth.

Most Popular Narrative: 29.1% Undervalued

ICON’s most followed valuation narrative places fair value at $142.86 per share, versus a last close of $101.28, framing the current discount as substantial.

Operational standardization and streamlining processes are expected to enhance ICON's study cycle times and operational efficiencies, potentially improving net margins and profitability. Strategic investments in AI-enabled tools like iSubmit and SmartDraft are set to accelerate trials and enhance data management, which could lead to improved earnings through increased operational efficiency.

Read the complete narrative.

Want to see what kind of trial volumes, margins and earnings power would justify that higher fair value? The most followed narrative lays out a detailed playbook, including how efficiency tools and capital allocation tie into future profit per share and the valuation multiple backing that $142.86 figure.

Result: Fair Value of $142.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on the accounting investigation and potential backlog restatements, which could reshape reported earnings and keep cancellation and margin pressures in focus.

Find out about the key risks to this ICON narrative.

Next Steps

If this mix of concern and optimism around ICON has you undecided, take a closer look at the data now and weigh both sides of the story. Then stress test your view against the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with ICON alone. Widen your watchlist using focused stock ideas that match how you like to balance risk, value and income.

• Target potential bargains with strong fundamentals by scanning 58 high quality undervalued stocks before prices better reflect those strengths.
• Prioritise capital protection and steadier returns by reviewing companies in the 73 resilient stocks with low risk scores while conditions still look reasonable.
• Spot companies that the market may be overlooking by checking the screener containing 25 high quality undiscovered gems before they draw wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com